TriangleHEALTH PROFESSIONAL · SOURCE READING
Stem cell transplant
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
In many institutions, autologous or allogeneic SCTs are being used for high-risk patients whose disease has relapsed rapidly after chemoimmunotherapy. Such an approach is considered in the context of numerous other available agents.[33-37]
Evidence (SCT):
The German Low-Grade Lymphoma Study Group treated 307 patients with follicular lymphoma with two cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like induction chemotherapy and then randomly assigned them to receive autologous SCT or interferon maintenance.[38]
Source links and citations
The German Low-Grade Lymphoma Study Group treated 307 patients with follicular lymphoma with two cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like induction chemotherapy and then randomly assigned them to receive autologous SCT or interferon maintenance.[38]
With a median follow-up of 4.2 years, the 5-year PFS rate was 65% for patients who received a transplant versus 33% for patients who received interferon (P < .001). There was no difference in OS.[38][Level of evidence B1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice